ecancermedicalscience

Review

Current landscape of BRAF-V600E metastatic CRC management in Latin America: an expert Latin American panel’s recommendations

4 Dec 2024
Anelisa K Coutinho, Yazmin Carolina Blanco Vazquez, Markus Andret Cavalcante Gifoni, Angela Marie Jansen, Juan Manuel O’Connor, Juan Carlos Samamé Pérez-Vargas, Mariana Rico-Restrepo, Gayatri Sanku, Guillermo Mendez

Colorectal cancer is the second leading cause of cancer death in Latin America (LA) with a projected 65.4% increase by 2040. Up to 10% of metastatic CRC (mCRC) patients in LA had an activating BRAF mutation. In clinical trials, targeted therapies for BRAF-V600E mutated mCRC have improved patient outcomes. However, in LA, BRAF-V600E testing and treatment of positive patients remains variable. To address this need, the Americas Health Foundation convened a meeting of LA experts on BRAF-V600E mCRC to develop treatment recommendations. The expert panel addressed the current landscape of BRAF-V600E mCRC testing, diagnosis and treatment in the region and identified significant limitations. Local guidelines, multidisciplinary boards, and tumor genotyping are among the recommendations. The panel also made first-line, second-line and surgery recommendations for patients after diagnosis.

Related Articles

Afusat O Oduwoye, Elisha O Olabisi, Elizabeth F Ojo, Taiwo O Dosumu, Michael O Owoeye, Adelani Tijani, Deborah T Esan
Yanet Isabel Carrasco Rojas, Albert Gabriel Turpo Peqqueña, Natalia Camila Zenteno Tejada, Victoria Elena Quispe Pastor, Juan Augusto Martínez San Martín, Evelyn Maria Chambilla Huellcacure
Jeanine Justiniano, Ally H Mwanga, Daniel W Kitua, Nashivai E Kivuyo, Seif Wibonela, Cameron E Gaskill
Joaquin Fernandez-Alberti, Alex R Villaalta López, Guillermo Scolari, Alejandro Iotti, Marcelo Featherston